$6.95
+0.63 (+9.97%)
AVX News4 articles
Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan
Novavax shares slipped 0.6% to $9.00 after regulatory approvals for its updated vaccine in the US, EU, and Japan. The company now relies on partners like Sanofi for commercialization, with royalties expected but not yet in guidance.
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Novavax Surges on Pfizer Deal, Beats Q1 Revenue Forecasts
Novavax topped Q1 revenue estimates at $139.5M, driven by a $30M Pfizer payment, offsetting weak COVID vaccine sales. Shares rose 15.6%.